FDA Clearance Impact: Recent discussions on social media about Tempus AI, Inc. have heavily focused on the company’s FDA 510(k) clearance for AI-driven diagnostic tools. Many view this as a significant step forward for precision medicine, especially in oncology. The buzz reflects optimism about the firm’s potential growth in the healthcare AI space.
Stock Price Decline: Conversations also highlight a recent 9% drop in TEM’s stock price over the past week, sparking varied reactions. Some users are pointing to technical patterns, suggesting a possible bounce or breakout, while others remain cautious due to bearish trends. Insider selling, including a large transaction by the CEO, has added fuel to the debate about the stock’s near-term direction.
Technical and Fundamental Outlook: There’s a split in opinions on social media regarding TEM’s future, with some emphasizing strong fundamentals like revenue growth and others focusing on key resistance levels. The mix of AI innovation and market dynamics keeps the dialogue lively. Many are watching for a trend reversal or confirmation of support levels to gauge momentum.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI, Inc. Insider Trading Activity
Tempus AI, Inc. insiders have traded $TEM stock on the open market 121 times in the past 6 months. Of those trades, 0 have been purchases and 121 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
- ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 66 sales selling 1,696,787 shares for an estimated $127,005,580.
- THEODORE LEONSIS has made 0 purchases and 2 sales selling 64,000 shares for an estimated $4,592,200.
- RYAN FUKUSHIMA (Chief Operating Officer) has made 0 purchases and 20 sales selling 57,559 shares for an estimated $4,308,740.
- JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 7 sales selling 34,751 shares for an estimated $2,499,084.
- ANDREW POLOVIN (EVP and General Counsel) has made 0 purchases and 9 sales selling 29,864 shares for an estimated $2,144,365.
- ERIK PHELPS (EVP & Chief Admin & Legal Off) has made 0 purchases and 5 sales selling 8,499 shares for an estimated $592,859.
- WAYNE A.I. FREDERICK sold 3,675 shares for an estimated $283,820
- RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 4 sales selling 3,738 shares for an estimated $262,337.
- JENNIFER A DOUDNA has made 0 purchases and 3 sales selling 3,227 shares for an estimated $227,759.
- DAVID R EPSTEIN has made 0 purchases and 4 sales selling 1,240 shares for an estimated $91,006.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Tempus AI, Inc. Revenue
Tempus AI, Inc. had revenues of $334.2M in Q3 2025. This is an increase of 84.72% from the same period in the prior year.
You can track TEM financials on Quiver Quantitative's TEM stock page.
Tempus AI, Inc. Hedge Fund Activity
We have seen 253 institutional investors add shares of Tempus AI, Inc. stock to their portfolio, and 169 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GOLDMAN SACHS GROUP INC removed 4,030,697 shares (-94.7%) from their portfolio in Q3 2025, for an estimated $325,317,554
- NEA MANAGEMENT COMPANY, LLC removed 2,615,979 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $166,219,305
- BLACKROCK, INC. added 2,597,838 shares (+62.8%) to their portfolio in Q3 2025, for an estimated $209,671,504
- BAILLIE GIFFORD & CO removed 2,401,588 shares (-19.9%) from their portfolio in Q3 2025, for an estimated $193,832,167
- VANGUARD GROUP INC added 1,706,837 shares (+22.1%) to their portfolio in Q3 2025, for an estimated $137,758,814
- D. E. SHAW & CO., INC. added 1,605,757 shares (+380.8%) to their portfolio in Q3 2025, for an estimated $129,600,647
- BANK OF AMERICA CORP /DE/ added 1,277,244 shares (+112.9%) to their portfolio in Q3 2025, for an estimated $103,086,363
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Tempus AI, Inc. Government Contracts
We have seen $18,460,020 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ADAPT CRO SUPPORT SERVICES SOLICITATION: $12,741,975
- TUMOR NORMAL MATCHED GENOMIC TESTING SERVICES: $5,718,045
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Tempus AI, Inc. Analyst Ratings
Wall Street analysts have issued reports on $TEM in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 12/22/2025
- BTIG issued a "Buy" rating on 11/25/2025
- Morgan Stanley issued a "Overweight" rating on 11/11/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/07/2025
- Guggenheim issued a "Buy" rating on 09/26/2025
To track analyst ratings and price targets for Tempus AI, Inc., check out Quiver Quantitative's $TEM forecast page.
Tempus AI, Inc. Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 8 analysts offer price targets for $TEM in the last 6 months, with a median target of $87.0.
Here are some recent targets:
- Kyle Mikson from Canaccord Genuity set a target price of $80.0 on 12/22/2025
- Casey Woodring from JP Morgan set a target price of $80.0 on 12/15/2025
- Tejas Savant from Morgan Stanley set a target price of $85.0 on 12/02/2025
- Mark Massaro from BTIG set a target price of $105.0 on 11/25/2025
- David Westenberg from Piper Sandler set a target price of $80.0 on 11/11/2025
- Yi Chen from HC Wainwright & Co. set a target price of $89.0 on 11/07/2025
- Ryan MacDonald from Needham set a target price of $100.0 on 11/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
